The Health and Human Services Department is withdrawing a proclamation broadly calling on drugmakers to offer hotly contested price discounts for low-income health-care providers in an attempt to fend off litigation, but the agency won’t back down from fighting individual companies. The HHS’ 2020 advisory opinion calling on pharmaceutical companies participating in the government’s 340B program to […]
Read MoreNEWS CATEGORY: Pharma
Senate Democrats begin updating their 2019 drug pricing bill, despite Republican skepticism.
Senate Finance Chair Ron Wyden (D-Ore.) confirmed in a hearing this morning that he’s begun updating the 2019 bill he co-authored with Sen. Chuck Grassley (R-Iowa) that would have cut subsidies from drug companies that raised prices more than the cost of inflation, POLITICO’s Alice Miranda Ollstein reports. Specifically, Wyden said he plans to add some kind of Medicare price negotiation […]
Read MoreLobbyists Say Democrats Have New Plan For Passing Drug Pricing Bill
Democrats are considering adding Medicare drug price negotiation to the president’s American Families Plan and using budget reconciliation to pass it separately from the infrastructure bill, if a bipartisan deal is struck on infrastructure, drug and consumer lobbyists said. Yet key lawmakers are also going through the motions of negotiating a bipartisan drug-pricing bill. Senate […]
Read MoreHHS May Revamp Reimbursement Policies For Critical Medicines
The Biden administration has asked HHS to study whether new reimbursement policies could be used to shore up domestic supplies of critical medicines, including the possibility of new federal payment policies that hike profit margins for certain generic sterile injectables and cancer drugs, procurement guarantees and flexible acquisition policies. Overhauling reimbursement is one of several ways […]
Read MoreBiden Plans Federal-Private Consortia To Steer Drug Supply Chain Plan
The White House has asked HHS to lead a consortium comprising nearly a dozen federal agencies, the private sector and nonprofit entities charged with crafting a strategy to secure the pharmaceutical supply chain by boosting U.S. production, developing new manufacturing technologies, and increasing the resilience of U.S. and allied pharmaceutical production. The White House will […]
Read MoreBiden to shore up supply chains for four sectors after 100-day reviews
President Joe Biden will direct federal agencies to shore up production and delivery of pharmaceuticals, computer chips, advanced batteries and critical minerals after completing reviews of their supply chains. New task forces, production rules: The actions include a $60 million investment in research for advanced pharmaceutical manufacturing through the Department of Health and Human Services, and […]
Read MoreDemocratic lawmakers see path for advancing drug price reforms
President Joe Biden wants to keep drug pricing separate from his new sweeping economic package. But some key Democratic lawmakers said they heard another message in his address to Congress on Wednesday night. Senior Democratic leaders on health care are taking Biden’s endorsement of government drug price negotiations as a green light to try to […]
Read More